Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Impaired activation of murine platelets lacking Gαi2
Hans-Michael Jantzen, … , Pamela B. Conley, Richard M. Mortensen
Hans-Michael Jantzen, … , Pamela B. Conley, Richard M. Mortensen
Published August 1, 2001
Citation Information: J Clin Invest. 2001;108(3):477-483. https://doi.org/10.1172/JCI12818.
View: Text | PDF
Article

Impaired activation of murine platelets lacking Gαi2

  • Text
  • PDF
Abstract

The intracellular signaling pathways by which G protein–coupled receptors on the platelet surface initiate aggregation, a critical process for hemostasis and thrombosis, are not well understood. In particular, the contribution of the Gi pathway has not been directly addressed. We have investigated the activation of platelets from mice in which the gene for the predominant platelet Gαi subtype, Gαi2, has been disrupted. In intact platelets from Gαi2-deficient mice, the inhibition of adenylyl cyclase by ADP was found to be partially impaired compared with wild-type platelets. Moreover, both ADP-dependent platelet aggregation and the activation of the integrin αIIbβ3 (GPIIb-IIIa) were strongly reduced in platelets from Gαi2-deficient mice. In addition, Gαi2-deficient platelets displayed impaired activation at low thrombin concentrations. This defect was mimicked by blocking the adenylyl cyclase–coupled platelet ADP receptor (P2Y12) on wild-type platelets with a selective antagonist. These observations suggest that Gαi2 is involved in the inhibition of platelet adenylyl cyclase in vivo and is a critical component of the signaling pathway for integrin activation by ADP, resulting in platelet aggregation. In addition, thrombin-dependent activation of mouse platelets is mediated, at least in part, by secreted ADP acting on the Gαi2–linked ADP receptor.

Authors

Hans-Michael Jantzen, David S. Milstone, Laurent Gousset, Pamela B. Conley, Richard M. Mortensen

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Stimulation of FITC-fibrinogen binding to platelets from Gαi2–/– mice. (...
Stimulation of FITC-fibrinogen binding to platelets from Gαi2–/– mice. (a and b) Diluted PRP from wild-type (filled bars) and Gαi2 knockout mice (open bars) was incubated with FITC-fibrinogen in the absence (Control) and presence of increasing concentrations of ADP and thrombin. The mean fluorescence intensity of platelet-bound FITC-fibrinogen was determined by flow cytometry. (c) Blockade of thrombin-mediated stimulation of FITC-fibrinogen binding by the P2Y12 ADP receptor antagonist 2MeSAMP. Platelets from wild-type mice treated with thrombin were incubated in the absence (filled bars) and presence of the P2Y12 ADP receptor antagonist 2MeSAMP (gray bars). Data shown are the mean ± SEM of one representative experiment out of at least three performed in duplicate.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts